Literature DB >> 6850656

Phase II study of etoposide in the treatment of esophageal carcinoma.

C J Coonley, M Bains, R Heelan, M Dukeman, D P Kelsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6850656

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  9 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 2.  Update in cancer chemotherapy: gastrointestinal cancer, cancer of the small intestines, gallbladder, liver, and esophagus.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-08       Impact factor: 1.798

3.  Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.

Authors:  Elisabeth I Heath; Susan Urba; John Marshall; Steven Piantadosi; Arlene A Forastiere
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

4.  13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial.

Authors:  C F Slabber; G Falkson; W Burger; L Schoeman
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus.

Authors:  A Harstrick; C Bokemeyer; P Preusser; C H Köhne-Wömpner; H J Meyer; M Stahl; H Knipp; H J Schmoll; H Wilke
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Esophageal cancer chemotherapy: recent advances.

Authors:  David H Ilson
Journal:  Gastrointest Cancer Res       Date:  2008-03

7.  Trimetrexate in advanced carcinoma of the esophagus.

Authors:  A S Alberts; G Falkson; M Badata; A P Terblanche; E U Schmid
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

8.  Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Atsuko Yamada; Toshiyuki Tanahashi; Naoki Okumura; Nobuhisa Matsuhashi; Kazuya Yamaguchi; Tatsuhiko Miyazaki
Journal:  Cancer Chemother Pharmacol       Date:  2016-02-20       Impact factor: 3.333

9.  Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.

Authors:  T C Kok; A Van der Gaast; J Dees; W M Eykenboom; H Van Overhagen; G Stoter; H W Tilanus; T A Splinter
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.